EP4213815A1 - Composition de capsule d'anagrélide stable à long terme - Google Patents
Composition de capsule d'anagrélide stable à long termeInfo
- Publication number
- EP4213815A1 EP4213815A1 EP20954278.6A EP20954278A EP4213815A1 EP 4213815 A1 EP4213815 A1 EP 4213815A1 EP 20954278 A EP20954278 A EP 20954278A EP 4213815 A1 EP4213815 A1 EP 4213815A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- anagrelide
- lactose
- pharmaceutical composition
- capsule
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007963 capsule composition Substances 0.000 title claims abstract description 17
- 230000007774 longterm Effects 0.000 title claims abstract description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 20
- 239000008101 lactose Substances 0.000 claims abstract description 20
- ULNVBRUIKLYGDF-UHFFFAOYSA-N 1,3-bis(4-methylphenyl)thiourea Chemical group C1=CC(C)=CC=C1NC(=S)NC1=CC=C(C)C=C1 ULNVBRUIKLYGDF-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960003555 anagrelide hydrochloride Drugs 0.000 claims abstract description 13
- 229960001694 anagrelide Drugs 0.000 claims description 46
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 20
- 229960001375 lactose Drugs 0.000 claims description 19
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 15
- 229960001021 lactose monohydrate Drugs 0.000 claims description 15
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 claims description 12
- 239000007884 disintegrant Substances 0.000 claims description 11
- 239000000314 lubricant Substances 0.000 claims description 10
- 239000011230 binding agent Substances 0.000 claims description 9
- 239000000945 filler Substances 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 229940069328 povidone Drugs 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 229960000913 crospovidone Drugs 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 6
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 6
- 238000005550 wet granulation Methods 0.000 claims description 4
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 claims 1
- 239000012535 impurity Substances 0.000 abstract description 11
- 229940050551 anagrelide 0.5 mg Drugs 0.000 abstract description 5
- 238000000354 decomposition reaction Methods 0.000 abstract description 5
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract description 4
- TVWRQCIPWUCNMI-UHFFFAOYSA-N anagrelide hydrochloride Chemical compound Cl.N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 TVWRQCIPWUCNMI-UHFFFAOYSA-N 0.000 description 55
- 239000000047 product Substances 0.000 description 30
- 239000002775 capsule Substances 0.000 description 22
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 21
- 238000012360 testing method Methods 0.000 description 16
- 239000003814 drug Substances 0.000 description 14
- 229940060238 agrylin Drugs 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 230000015556 catabolic process Effects 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 7
- 201000010538 Lactose Intolerance Diseases 0.000 description 7
- 235000020937 fasting conditions Nutrition 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 239000007857 degradation product Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 229960004977 anhydrous lactose Drugs 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000007922 dissolution test Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000013446 two one sided t-test Methods 0.000 description 4
- 208000022120 Jeavons syndrome Diseases 0.000 description 3
- 102100040402 Phlorizin hydrolase Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KJMFQJFNQYWQAV-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinazoline Chemical class C1=NC=NC2=C(NC=N3)C3=CC=C21 KJMFQJFNQYWQAV-UHFFFAOYSA-N 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010059881 Lactase Proteins 0.000 description 2
- 108010059801 Lactase-Phlorizin Hydrolase Proteins 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000014754 thrombocytosis disease Diseases 0.000 description 2
- XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- LXLOZUWWCLJYGV-UHFFFAOYSA-N 2-(2-amino-5,6-dichloro-4h-quinazolin-3-yl)acetic acid Chemical compound C1=C(Cl)C(Cl)=C2CN(CC(O)=O)C(N)=NC2=C1 LXLOZUWWCLJYGV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010023648 Lactase deficiency Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000009506 drug dissolution testing Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 229940000673 orphan drug Drugs 0.000 description 1
- 239000002859 orphan drug Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035921 thrombopoiesis Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000723 toxicological property Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Definitions
- the present invention relates to formulate pharmaceutical capsule composition comprising anagrelide hydrochloride, a process for the manufacture of said formulation with long-term storage stable properties.
- Anagrelide (Imidazo (2,1 -b) quinazolin-2 (3H)-one,6,7-dichloro-1 ,5-dihydromono hydrochloride) is a pharmaceutically active compound useful for the treatment of essential thrombocythaemia (ET). Its molecular formula is C10H7CI2N3O and it is represented by Formula I (shown below);
- Anagrelide was first disclosed in US 3932407 as a compound useful at blood platelet anti-aggregative and/or antihypertensive and/or bronchodilator agents in mammals, including humans. In 1997, anagrelide was approved in the United States as a therapeutic agent for thrombocytosis associated with myeloproliferative neoplasm; in 2004, it was approved in Europe for the treatment of high-risk essential thrombocythemia patients.
- Essential thrombocythaemia which is the most often occurring myeloproliferative disorder is a clonal malignant disorder arising from stem cell. It is a myeloproliferative neoplasm (MPN), which is, characterized by a sustained platelet increase in the peripheral blood and anomalous megakaryocyte growth in bone marrow biopsy.
- Treatment goals comprise prevention of thrombohemorrhagic events (THEs), progression to myelofibrosis (MF) or acute leukemia (AL), and the onset of secondary malignancies.
- TEEs thrombohemorrhagic events
- MF myelofibrosis
- AL acute leukemia
- Anagrelide anagrelide hydrochloride
- is an imidazoquinazoline derivative which lowers platelet count probably by inhibiting thrombopoiesis and reduces platelet aggregation.
- Anagrelid is marketed with names Thromboreductin® and Xagrid® (or Agrylin®) and these are oral imidazoquinazolines registered as orphan drugs in Europe.
- Xagrid® (or Agrylin®) is an immediate release capsule which releases more than 90% of its active in vitro within the first 10 minutes. It is medicinal product indicated for the reduction of elevated platelet counts in at risk ET patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.
- Xagrid® is in the form of hard gelatin capsules, each of which contains anagrelide hydrochloride equivalent to 0.5 mg of anagrelide.
- Agrylin® (Shire US Inc.) is used for reference product.
- EP1351668B1 and EP1351668B1 disclose pharmaceutical compositions with sustained release dissolution profiles.
- EP2367539B1 (AOP Orphan Pharmaceutical) relates to a novel pharmaceutical composition comprising anagrelide hydrochloride in combination with lactose monohydrate and its use for the treatment of essential thrombocythemia. It is related to non-immediate and highly consistent release pharmaceutical composition.
- EP2549983 B1 (AOP Orphan Pharmaceutical) relates to a novel pharmaceutical composition comprising anagrelide hydrochloride in combination with a non-pH dependent polymer and a pharmaceutically acceptable watersoluble acid and its use for the treatment of essential thrombocythemia.
- EP2915526A1 discloses a pharmaceutical composition of anagrelide hydrochloride monohydrate having a low content of total impurities originating from the decomposition of anagrelide hydrochloride monohydrate.
- prepared capsules were subjected to stability tests at time 0 and 1 month or 53 days at 25°C/ 60% relative humidity (RH), 30°C/ 65% RH, 30°C/ 75% RH and 40°C/ 75% RH.
- the problem for the anagrelide capsule composition is the high use of lactose.
- the reference products, Xagrid® (Agrylin®) capsule comprises a combination of 53.7 mg lactose monohydrate and 65.8 mg anhydrous lactose and Thromboreductin® comprises 93.9 mg lactose monohydrate.
- Lactase is a disacharidase (P-galactosidase) expressed on the tips of the villi of the small intestine having the ability to hydrolyze lactose into galactose and glucose.
- lactasephlorizin hydrolase (LPH) activity is responsible for lactose intolerance/malabsorption leading to diarrhea, abdominal pain or bloating after lactose ingestion.
- LPH lactasephlorizin hydrolase
- Typical treatments for lactose intolerance is by decreasing the amount of lactose in the diet, taking lactose supplements, or treating the underlying disease.
- It is an object of the present invention to provide a stable pharmaceutical composition comprising therapeutically effective amount of anagrelide or a pharmaceutically acceptable salt thereof having immediate release properties and low amount of lactose content.
- the present invention provides a stable immediate release Anagrelide 0.5 mg capsule composition having low content of total impurities originating from the decomposition of anagrelide hydrochloride.
- a long-term stable oral pharmaceutical capsule composition comprises anagrelide or a pharmaceutically acceptable salt thereof as active ingredient, lactose monohydrate, lactose anhydrous and at least one other pharmaceutically acceptable excipient, wherein the weight ratio of lactose monohydrate to lactose anhydrous is about 2.5:1 .
- a long-term stable oral pharmaceutical capsule composition comprises anagrelide or a pharmaceutically acceptable salt thereof as active ingredient, lactose monohydrate, lactose anhydrous and at least one filler/diluent, disintegrant, binder and lubricant, wherein the weight ratio of lactose monohydrate to lactose anhydrous is about 2.5:1 .
- the active ingredient is anagrelide hydrochloride.
- the filler/diluent is a combination of lactose and microcrystalline cellulose.
- the disintegrant is crospovidone.
- the binder is povidone.
- the lubricant is magnesium stearate.
- a long-term stable oral pharmaceutical capsule composition comprises 0.57 mg anagrelide hydrochloride, 50.9 mg lactose monohydrate, 20.5 mg lactose anhydrate, 22.5 mg microcrystalline cellulose, 6.0 mg povidone, 5.5 mg crospovidone and 1.0 mg magnesium stearate, wherein the said composition is prepared by wet granulation process.
- anagrelide is used for pharmaceutically acceptable salts, hydrates and/or solvates thereof; anagrelide, anagrelide hydrochloride or anagrelide hydrochloride monohydrate are used interchangeably.
- stable refers to a pharmaceutical composition comprising anagrelide or a pharmaceutically acceptable salt thereof wherein the total content of degradation impurities originating from the decomposition of anagrelide does not exceed 2.0 % area and most preferably 1.5 % area determined as specified in the US Pharmacopoeia official monograph for anagrelide capsules.
- the term ‘long-term stable’ refers to a pharmaceutical composition comprising anagrelide or a pharmaceutically acceptable salt thereof wherein the total content of degradation impurities originating from the decomposition of anagrelide does not exceed 1 .5 % area determined as specified in the US Pharmacopoeia official monograph for anagrelide capsules for at least about 6 months at 40°C ⁇ 2°C, 75%RH ⁇ 5% and 24 months at 25°C ⁇ 2°C, 60% ⁇ 5% RH conditions.
- the active substance anagrelide hydrochloride is present in the form of micronized anagrelide having a particle size of D90 less than 10 pm and D50 less than 6 pm. It is important to use a small particle size raw material in order to eliminate the problems that may occur in content uniformity by preparing the capsule composition containing low concentration anagrelide active substance.
- D10 ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇
- the wet granulation method was preferred in the preparation of pharmaceutical dosage form.
- One or more pharmaceutically acceptable excipients used according to the invention includes without any limitations, those that are conventionally used, for the capsule dosage form e.g. fillers, diluents, disintegrants, binders and lubricants. Suitably, also other excipients that are appropriate for the chosen dosage form may be present. These excipients include but are not limited to coatings, colors, flavors, glidants, retardants, spheronisation aids etc. Some excipients present in the formulation according to the invention may have multiple functions.
- fillers fill out the size of a composition, making it practical to produce and convenient for the consumer to use.
- suitable filler/diluent include but are not limited to lactose, microcrystalline cellulose, mannitol, ethyl cellulose, sorbitol, starch, sucrose, calcium phosphate, powdered cellulose, silicified microcrystalline cellulose, isomalt, and mixtures thereof.
- lactose is widely used in pharmaceutical formulations as a diluent and filler-binder in oral capsule and tablet formulations.
- lactose as used herein comprises lactose monohydrate and/or lactose anhydrous.
- lactose monohydrate and lactose anhydrous are used together.
- Anhydrous lactose can be used with moisture-sensitive drugs due to its low moisture content.
- lactose anhydrous is incompatible with strong oxidizers.
- mixtures containing a hydrophobic leukotriene antagonist and anhydrous lactose or lactose monohydrate were stored for six weeks at 40°C and 75% RH, the mixture containing anhydrous lactose showed greater moisture uptake and drug degradation (Handbook of Pharmaceutical Excipients, 6 th Edition, Lactose Anhydrous, page 359-361). This is the reason for using lactose in a mixture of lactose monohydrate and lactose anhydrous instead of using only lactose anhydrous.
- lactose intolerance which occurs in individuals with a deficiency of the intestinal enzyme lactase, and is associated with oral ingestion of amounts well over those found in solid dosage forms. This is also critical for patients who have lactose intolerance. This is the reason for using lactose in minimum content.
- a disintegrant is a substance which helps the composition break up once ingested.
- suitable disintegrants include, but are not limited to one or more of starches, celluloses, algins, and cross-linked polymers.
- a group of disintegrants referred to as “super-disintegrants” are generally used at a low level in the solid dosage form, typically 1 to 10% by weight relative to the total weight of the dosage unit.
- super-disintegrants are croscarmelose, crospovidone and sodium starch glycolate, which represent examples of cross-linked cellulose, cross-linked polymer and cross-linked starch, respectively. In this present invention, crospovidone is used as a disintegrant.
- Suitable binders include, but are not limited to one or more of povidone, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose (HPMC), ethyl cellulose, sodium carboxymethyl cellulosexylitol, starch, and the like.
- povidone is used as a binder.
- povidone is used in a variety of pharmaceutical formulations, it is primarily used in solid-dosage forms. In the present invention, povidone is used in an amount of 1% to 7% based on total weight of the formulation.
- the pharmaceutical composition comprises magnesium stearate as a lubricant.
- Magnesium stearate is primarily used as a lubricant in capsule and tablet manufacture at concentrations between 0.25% and 5.0% w/w.
- the amount of magnesium stearate ranges from 0.8 to 1 .2% by weight in respect to the total amount of the pharmaceutical composition preferably ranges from 0.9 to 1.1% by weight in respect to the total amount of the pharmaceutical composition.
- magnesium stearate which is also included in the original content, was used to provide the desired powder flow from the final powder mixture. All ingredients used in Anagrelid 0.5 mg capsule production are standard excipients used in capsule formulations and all excipients are included in the European Pharmacopoeia monographs and comply with the relevant specifications.
- compositions of this invention are detailed below showing examples. However, pharmaceutical compounds of this invention are not restricted to the following examples.
- the granules of the composition are prepared by wet granulation with following formulation given at Table 1 .
- the preparation process of the granules is described as: a.
- the active agent, anagrelid hydrochloride, and at least one pharmaceutically acceptable excipient were weighed and mixed.
- b. The components of step (a) were added to a high shear mixer and granulated with water.
- c. The granules obtained from step (b) were dried in a fluidized bed dryer.
- the dried granules obtained from step (c) were grinded.
- At least one extra-granular pharmaceutically acceptable excipient was mixed with the dried granules obtained in step (d).
- a pharmaceutically acceptable lubricant is mixed with the granules obtained from step (e) before being encapsulated in hard capsules. Table 1.
- Comparative dissolution tests were conducted based on the general dissolution test method. The analysis was performed according to FDA Dissolution Methods - Anagrelide HCI Capsule. The progress of dissolution is monitored for 45 minutes (recommended sampling times: 5, 10, 15, 30 and 45 minutes). Dissolution test was performed at USP Apparatus I (basket), speed 100 rpm, 900 mL volume with 0.1 N HCI (FDA medium), pH 4.5 and pH 6.8 mediums. Dissolution testing measures the portion (%) of Anagrelide that has been released from capsule and has dissolved in the dissolution medium. Dissolved anagrelide content was determined spectrophotometrically by a validated HPLC method at 254 nm.
- Comparative dissolution tests were conducted with test products (F-01 , F-02, F-03 and F-04) and reference product of Agrylin® 0.5 mg Capsule.
- the conditional release profiles of the test products and reference product were plotted as the cumulative percent of drug dissolved vs. time.
- the dissolution profiles were compared; the dissolution profiles obtained were evaluated by similarity factor (£?) (Helmy & Bedaiwy, 2013).
- An /2 value between 50 and 100 suggests that the two dissolution profiles are similar (EMEA Guideline on the Investigation of Bioequivalence, 2010).
- test product of F-04 was selected for proceeding studies according to dissolution similarity results with reference product.
- the pharmaceutical anagrelide capsule composition according to the present invention exhibits a dissolution profile such that about 85% of the anagrelide is released within 15 minutes; and wherein the release rate is measured in USP Apparatus I (basket), speed 100 rpm, 900 mL volume with 0.1 N HCI (FDA medium) at 37°C ⁇ 0.5°C ( Figure I).
- the stability of a drug substance is an important factor in the manufacture of safe and effective pharmaceutical products. Stability studies are required to be submitted by any applicant seeking approval for a new pharmaceutical product.
- the rules in force e.g. "Note for Guidance on Impurities in New Drug Products” CPMP/ICH/2738/99, issued by EMEA, European Medicines Agency) provide strict limitations for impurities, nevertheless it is better to prevent or reduce as possible the degradation to avoid the exposure of patients to substances.
- the stability of a pharmaceutical dosage form is related to maintaining its physical, chemical, microbiological, therapeutic, and toxicological properties when stored, i.e., in a particular container and environment.
- Accelerated stability tests are performed by storing a product in stress conditions. These tests allow predicting the shelf life of the product over the years when it will be stored in normal storage conditions.
- the accelerated stability test in this case was performed according to the EMEA Guideline on Stability Testing (CPMP/QWP/ 122/02, rev 1), i.e. by maintaining the product in its container at a temperature of 40°C ⁇ 2°C and 75% ⁇ 5 %RH (Relative Humidity) for six months.
- the accelerated stability condition is temperature of 40°C ⁇ 2°C and 75 % ⁇ 5°C RH for up to 6 months and ambient stability condition is temperature of 25°C ⁇ 2°C and 60% ⁇ 5% RH for up to 24 months.
- Test product capsule formulations were packed in Alu-Alu containers and they were charged on to the stability cabinets. Samples were taken out at each stability stage interval and submitted for analysis. The results are summarized in the following Table 3.
- FDA United States Food and Drug Administration
- Reference drug means an anagrelide hydrochloride product as described in U.S. Federal Food and Drug Administration's New Drug Application No. 021368 approved on Nov 21 , 2003 as provided in the U.S. Federal Food and Drug Administration's Orange Book, Approved Drug Products with Therapeutic Equivalence Evaluations.
- the pharmacokinetic parameters were estimated by non-compartmental methods using actual elapsed time from dosing; maximum observed plasma concentration (C m ax), area under the plasma concentration versus time curve from time zero until infinity (AUCo-int), area under the plasma concentration versus time curve from time zero until time of last quantifiable concentration (AUCo-t).
- Anagrelide 0.5 mg capsule composition of present invention (Test product - F04; Anagrelide 0.5 mg capsule Batch No: 1910819001 ) against Agrylin® (Anagrelid HCI) Capsule, Shire US Inc. - USA (Batch No: AF9326E) as using an open-label, single dose, 2-period crossover, randomized design under fasting conditions.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TR2020/050858 WO2022060309A1 (fr) | 2020-09-18 | 2020-09-18 | Composition de capsule d'anagrélide stable à long terme |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4213815A1 true EP4213815A1 (fr) | 2023-07-26 |
EP4213815A4 EP4213815A4 (fr) | 2023-09-06 |
Family
ID=80776970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20954278.6A Pending EP4213815A4 (fr) | 2020-09-18 | 2020-09-18 | Composition de capsule d'anagrélide stable à long terme |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4213815A4 (fr) |
WO (1) | WO2022060309A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115381791B (zh) * | 2022-09-21 | 2023-06-16 | 迪沙药业集团有限公司 | 一种盐酸氟桂利嗪药物组合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT10562U3 (de) * | 2008-12-05 | 2010-01-15 | Aop Orphan Pharmaceuticals Ag | Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytämie |
ES2549106T3 (es) * | 2014-03-07 | 2021-12-21 | Galenicum Health S L U | Composiciones farmacéuticas que comprenden anagrelida |
WO2016198166A1 (fr) * | 2015-06-10 | 2016-12-15 | Disphar International B.V. | Formulation pharmaceutique améliorée |
US10022377B2 (en) * | 2015-12-02 | 2018-07-17 | Cipla Limited | Method of treating hypertension |
-
2020
- 2020-09-18 WO PCT/TR2020/050858 patent/WO2022060309A1/fr unknown
- 2020-09-18 EP EP20954278.6A patent/EP4213815A4/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2022060309A1 (fr) | 2022-03-24 |
EP4213815A4 (fr) | 2023-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1067936B1 (fr) | Procede utilisant des super-desintegrants dans la preparation de capsules ou de comprimes d'efavirenz a dissolution rapide | |
CZ295226B6 (cs) | Tableta obsahující jako účinnou složku terapeuticky účinné množství hydrobromidu galantaminu a způsob její přípravy | |
EP2729130B1 (fr) | Formulations combinées de darunavir | |
US8951504B2 (en) | (trimethoxyphenylamino) pyrimidinyl formulations | |
KR101197277B1 (ko) | 경구용 결핵의 치료용 또는 예방용 고형 제형 | |
WO2006134610A1 (fr) | Composition pharmaceutique d'efavirenz presentant un profil de dissolution ameliore | |
US20170231969A1 (en) | Pharmaceutical Compositions of Edoxaban | |
EP4213815A1 (fr) | Composition de capsule d'anagrélide stable à long terme | |
EP3437645B1 (fr) | Comprimé enrobé d'un film et présentant une stabilité chimique élevée de son principe actif | |
US8277840B2 (en) | Sustained release formulation of alprazolam | |
EP1594531B1 (fr) | Formulations stables au stockage et biologiquement stables d'inhibiteurs des ACE, et procedes d'elaboration correspondants | |
TR2023002775T2 (tr) | Uzun süreli̇ stabi̇l anagreli̇d kapsül bi̇leşi̇mi̇ | |
CN109475557B (zh) | 含有甲氨蝶呤的薄膜包衣片 | |
US20030004130A1 (en) | Homogeneous pharmaceutical compositions containing zidovudine and lamivudine | |
EP4238555A2 (fr) | Combinaison à dose fixe et à libération immédiate de mémantine et de donépézil | |
EP3761965A1 (fr) | Formulation de comprimé contenant du ticagrelor | |
EP4374853A1 (fr) | Formulation solide d'enzalutamide | |
US8377979B2 (en) | Pharmaceutical formulation containing phenytoin sodium and magnesium stearate | |
EP3409294A1 (fr) | Comprimés contenant du cilostazol de distribution granulométrique spécifique | |
JPH0818985B2 (ja) | 溶出性の改良された製剤組成物 | |
CN114762687A (zh) | 一种钾离子竞争性酸阻滞剂的预混物及其制备 | |
CA2671778A1 (fr) | Forme posologique a liberation immediate de bosentan et procede de fabrication de ladite forme posologique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230313 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20230807 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/16 20060101ALI20230801BHEP Ipc: A61K 31/7016 20060101ALI20230801BHEP Ipc: A61K 31/519 20060101ALI20230801BHEP Ipc: A61K 9/48 20060101AFI20230801BHEP |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |